Cypherpunk Swings To Q2 Profit On Zcash Treasury Gains; Advances Phase 3 Sirexatamab Plans;Stock Up
Cypherpunk Technologies (CYPH) reported a Q2 profit of $39.4M, driven by a $46M gain on Zcash (ZEC) holdings. The company holds 323,394.38 ZEC, valued at $129.4M. Leap Therapeutics, a subsidiary, is advancing sirexatamab for mCRC with FDA alignment on a Phase 3 trial. CYPH stock rose 35.12% to $2.27.



